EQT agrees EUR 46.50 offer for Qiagen stock at 40.3 percent premium

Published on 10/23/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock costs EUR 45.03 on October 23, 2026, 0.20 percent above the Xetra close. Preliminary third-quarter sales reached USD 548 million.

Transaction terms and reporting calendar

EQT offered EUR 46.50 per Qiagen share on October 21, 2026, a 40.30 percent premium.
Preliminary third-quarter sales reached USD 548 million and adjusted earnings per share were USD 0.65.
Qiagen stock traded at EUR 45.03 at 10:31 a.m. CEST on October 23, 2026, 0.20 percent above the Xetra close of EUR 44.94 on October 22, 2026.
Qiagen plans to publish full third-quarter results on November 4, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0015002SN0) was trading at EUR 45.03 at Lang & Schwarz on October 23, 2026, at 10:31 a.m. CEST, up 0.20 percent versus the Xetra close. On October 21, 2026, QIAGEN agreed to an all-cash takeover offer from EQT at EUR 46.50 per share.

Deal terms set the valuation

The offer values Qiagen at approximately EUR 10.8 billion in enterprise value and represents a 40.30 percent premium to the unaffected Xetra price of EUR 33.15 on July 8, 2026. The official release also put the premium at 46.90 percent against the three-month Xetra volume-weighted average price of EUR 31.66 through that date.

Qiagen's supervisory and managing boards unanimously approved the agreement and recommended acceptance. The offer requires approval from holders of at least 50 percent of the outstanding share capital plus one share, alongside regulatory clearances, while completion is expected in mid-2027.

What does the latest quarter show?

Preliminary third-quarter net sales reached USD 548 million, while adjusted diluted earnings per share were USD 0.65. QIAGEN said it had suspended its full-year 2026 outlook while the transaction remained pending, adding a constraint to standalone valuation analysis.

Three dates explain the sequence

On July 8, 2026, the unaffected Xetra price was EUR 33.15. On October 21, 2026, preliminary third-quarter sales reached USD 548 million. On October 21, 2026, EQT announced the EUR 46.50 offer. This sequence links the takeover premium to both the recent operating update and the earlier unaffected price.

Dates investors can track

Qiagen plans to publish full third-quarter results on November 4, 2026, at approximately 22:05 Frankfurt time, according to its results release. The expected transaction closing date is mid-2027, subject to acceptance and regulatory conditions.

Stock stays below the offer price

The EUR 1.47 gap between the Lang & Schwarz quote and the proposed offer price leaves the takeover terms as the central reference for the stock. The market capitalization shown in the company snapshot was USD 10.3 billion as of October 22, 2026, while the 52-week range was USD 32.53 to USD 57.82.

Qiagen was trading at EUR 45.03 at Lang & Schwarz on October 23, 2026, at 10:31 a.m. CEST, 0.20 percent above the Xetra close of EUR 44.94 on October 22, 2026. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.